Document Detail

Ondansetron: a serotonin receptor (5-HT3) antagonist for antineoplastic chemotherapy-induced nausea and vomiting.
MedLine Citation:
PMID:  1833888     Owner:  NLM     Status:  MEDLINE    
Ondansetron represents a new class of drugs that exert their antiemetic activity by selective inhibition of a serotonin receptor subtype (5-HT3). Ondansetron has marked activity against emesis associated with cisplatin and other highly emetogenic drugs. Compared with high doses of metoclopramide, the antiemetic "gold standard," it demonstrates equal or superior efficacy. Although ondansetron is moderately well absorbed after oral administration, only a parenteral formulation will initially be available. Ondansetron is eliminated almost entirely by hepatic metabolism; less than five percent of an intravenously administered dose is recovered intact in urine. The half-life of ondansetron is approximately 3.5 hours; slightly shorter in children and prolonged in the elderly. Neither clinical efficacy nor adverse effects have correlated with serum concentrations. Ondansetron is generally well tolerated. Clinically relevant adverse effects include headache, diarrhea or constipation, sedation, and transient minor elevations of liver function tests. It is not associated with extrapyramidal reactions. Ondansetron is indicated as prophylaxis for nausea and vomiting associated with emetogenic chemotherapy. Studies to further evaluate and define its use are ongoing.
D R Kohler; B R Goldspiel
Related Documents :
6384428 - Adverse reactions to psychedelic drugs. a review of the literature.
19125128 - Recommendations from the egapp working group: can ugt1a1 genotyping reduce morbidity an...
21237258 - Mathematical modeling of simultaneous drug release and in vivo absorption.
16615658 - Adverse drug reactions reporting at a referral hospital in zimbabwe.
23488108 - Price pressure. as the number of costly specialty drugs grows, insurers and providers p...
10155678 - Treatment of osteomyelitis by antibiotic impregnated porous hydroxyapatite block.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  DICP : the annals of pharmacotherapy     Volume:  25     ISSN:  1042-9611     ISO Abbreviation:  DICP     Publication Date:  1991 Apr 
Date Detail:
Created Date:  1991-11-08     Completed Date:  1991-11-08     Revised Date:  2005-11-16    
Medline Journal Info:
Nlm Unique ID:  8904338     Medline TA:  DICP     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  367-80     Citation Subset:  IM    
Department of Pharmacy, Warren G. Magnuson Clinical Center, Bethesda, MD 20892.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / adverse effects*
Imidazoles / therapeutic use*
Nausea / chemically induced,  drug therapy*
Serotonin Antagonists / therapeutic use*
Vomiting / chemically induced,  drug therapy*
Reg. No./Substance:
0/Antineoplastic Agents; 0/Imidazoles; 0/Serotonin Antagonists; 99614-02-5/Ondansetron

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Right heart function and endotoxemia in animals
Next Document:  Type of posture and RI + SIII index in Einthoven's bipolar limb ECG in left heart hypertrophy caused...